http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-1338272-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_8cbda39cb08dc85c7b6b8d1e7d8985c6 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-1075 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-008 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-006 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-107 |
| filingDate | 1999-12-16^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_15c31a60bc7f3449e26907be39b47b21 |
| publicationDate | 2003-08-27^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | EP-1338272-A1 |
| titleOfInvention | Aerosol formulations for buccal and pulmonary application comprising chenodeoxycholate or deoxycholate |
| abstract | A mixed micellar aerosol pharmaceutical formulation includes a micellarnproteinic pharmaceutical agent, an alkali metal lauryl sulphate, a phenol, anpropellant, chenodeoxycholate or deoxycholate and at least two micelle formingncompounds are selected from the group consisting of lecithin, hyaluronic acid,npharmaceutically acceptable salts of hyaluronic acid, glycolic acid, lactic acidnchamomile extract, cucumber extract, oleic acid, linoleic acid, linolenic acid,nmonoolein, monooleates, monolaurates, borage oil, evening of primrose oil,nmenthol, trihydroxy oxocholanyl glycine and pharmaceutically acceptable saltsnthereof, glycerin, polyglycerin, lysine, polylysine, triolein, polyoxyethylenenethers and analogues thereof, polidocanol alkyl ethers and analogues thereof,nchenodeoxycholate and deoxycholate. The amount of each micelle formingncompound is present in a concentration of from 1 to 20 wt./wt.% of the totalnformulation, and the total concentration of micelle forming compounds are lessnthan 50 wt./wt.% of the formulation. The propellant, e.g., a fluorocarbonnpropellant, provides enhanced absorption of the pharmaceutical agent,nparticularly in the buccal cavity. |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-2674417-A2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/AU-2010323117-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-2088154-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2019183245-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2011064316-A3 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-2628727-A2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10966943-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-2476680-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2020142485-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9445992-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2009015037-A2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2010059836-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2010084499-A2 |
| priorityDate | 1998-12-21^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Showing number of triples: 1 to 307 of 307.